ASX ANNOUNCEMENT

20 August 2026

APPOINTMENT OF GROUP CHIEF FINANCIAL OFFICER

Little Green Pharma Ltd (ASX:LGP) (**LGP** or the **Company**) is pleased to announce the appointment of Ms Jennifer Pilcher as Chief Financial Officer (**CFO**).

Ms Pilcher is a highly experienced ASX executive with extensive finance, commercial and leadership experience across Australia, North America and Asia. She brings valuable and directly relevant medicinal cannabis industry experience from her six years at Cann Group, most recently serving for two years as CEO & Managing Director. Prior to Cann Group, Ms Pilcher held CFO roles across a number of ASX-listed life sciences and technology businesses.

Ms Pilcher's deep expertise in finance, commercial strategy and organisational leadership will be a significant asset to the LGP Cannatrek Group as it completes its post-merger integration and accelerates its international growth strategy.

Ms Pilcher will commence in the role on 24 August 2026.

ENDS
APPROVED FOR RELEASE

____
Alistair Warren
Company Secretary

Alistair Warren
Company Secretary
Little Green Pharma
E: cosec@lgp.global
T: +61 8 6280 0050

Paul Long
Group CEO
Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company, formed through the merger of Little Green Pharma and Cannatrek to create the LGP Cannatrek Group - one of the largest pure-play medicinal cannabis companies globally, with vertically integrated operations spanning cultivation, GMP-certified manufacturing, distribution, clinics and digital health across Europe and Australia.

The Group has a diverse and growing portfolio of cannabis-based medicines with products distributed across Australia and over eleven export markets via a network of wholesalers, pharmacies, clinics and GPs.

The Group operates major production facilities in Denmark and Australia, including the largest medicinal cannabis production facility in Europe, and ranks among the leading suppliers in Australia, Germany and France, positioning it as a key player in global medicinal cannabis markets.

Following completion of the merger on 1 June 2026, Cannatrek's strong balance sheet and cash-generative Australian operations are expected to provide a platform to scale the Group's Denmark facility and accelerate its expansion into European growth markets, while leveraging vertical integration and scale to sustain and improve margins across the combined business.

For more information about the LGP Cannatrek Group go to: https://investlittlegreenpharma.com/

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email to help reduce our costs and environmental footprint. To easily update your communication preferences, visit: www.investorcentre.com/au

Head Office PO Box 101, West Perth WA 6913 T + 61 8 6280 0050 E info@littlegreenpharma.com W littlegreenpharma.com